ZurückIndia's Pharma Industry Faces Profit Squeeze Amid Weak Rupee and Slowing Exports

In Entwicklung

Economic Times18.5.2026BusinessIndia

India's Pharma Industry Faces Profit Squeeze Amid Weak Rupee and Slowing Exports

pharmaceuticals rupee exports

Auf einen Blick

India's pharmaceutical sector is hit by rising import costs due to a weaker rupee and declining export demand from a global economic slowdown, squeezing manufacturer profits.
Companies are shifting to higher-margin products to cope.

KI-generierte Zusammenfassung

Schriftgröße

India's pharmaceutical sector is hit by rising import costs due to a weaker rupee and declining export demand from a global economic slowdown, squeezing manufacturer profits. Companies are shifting to higher-margin products to cope.

Read the full article on Economic Times

Ähnliche Meldungen

Mehr zu diesem Themapharmaceuticals

Business·vor 1 Stunde

Central Government Implements Employees' Pension Scheme 2026

India's central government has implemented the Employees' Pension Scheme (EPS) 2026, replacing the 1971 and 1995 schemes. While the pension calculation formula remains unchanged, new rules address fund investment, digital compliance, and offer 12% interest for delayed claims.

Economic Times

3 Min. Lesezeit

Business·vor 1 Stunde

Section 80CCD(2): Employer NPS contributions offer tax deduction under new regime

Section 80CCD(2) provides a significant tax deduction for employer contributions to the National Pension System (NPS), a benefit that remains available under India's new tax regime. This makes Corporate NPS particularly attractive for salaried individuals, especially those in the private sector, allowing them to reduce taxable income and build retirement savings.

Economic Times

5 Min. Lesezeit

Business·vor 2 Stunden

Legality of Extra Credit Card Charges for Indian Consumers

Merchants in India often charge extra for credit card payments, but experts state this is generally prohibited by card network rules and RBI regulations. The Merchant Discount Rate (MDR) is a fee paid by merchants, not customers, and funds card benefits. Many merchants prefer UPI due to lower costs.

Economic Times

5 Min. Lesezeit

Business·vor 2 Stunden

Taxpayers Must Promptly Respond to Income Tax Department's Section 143(1) Intimations

Taxpayers receiving Section 143(1) intimations from the Income Tax Department with tax demands must respond within 30 days. Failure to do so can lead to 1% monthly interest penalties, classification as an 'assessee in default,' and initiation of recovery proceedings, even if the demand is disputed.

Economic Times

5 Min. Lesezeit

In Entwicklung·vor 5 Stunden

Ford and Aramark Review Self-Service Kiosks After Employee Theft Allegations

Ford Motors and Aramark are reviewing self-service kiosks at US factories after employees were fired over alleged snack theft. Workers claim payment failures and software glitches caused wrongful accusations, leading to some reinstatements and widespread reluctance to use the kiosks.

Times of India

3 Min. Lesezeit

In Entwicklung·vor 5 Stunden

Johnson & Johnson's Ottava Robotic Surgical System Receives FDA Approval

Johnson & Johnson (J&J) has secured marketing authorization from the US FDA for its Ottava robotic surgical system, allowing it to enter the soft-tissue robotic surgery market. The system, approved for several general surgery procedures, will initially launch with select US customers, challenging Intuitive Surgical's dominance.

Times of India

2 Min. Lesezeit

Mehr zu diesem Themapharmaceuticals

India's Pharma Industry Faces Profit Squeeze Amid Weak Rupee and Slowing Exports

Auf einen Blick

Verwandte Themen

Ähnliche Meldungen

Central Government Implements Employees' Pension Scheme 2026

Section 80CCD(2): Employer NPS contributions offer tax deduction under new regime

Legality of Extra Credit Card Charges for Indian Consumers

Taxpayers Must Promptly Respond to Income Tax Department's Section 143(1) Intimations

Ford and Aramark Review Self-Service Kiosks After Employee Theft Allegations

Johnson & Johnson's Ottava Robotic Surgical System Receives FDA Approval